Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CureEB
- Development stage
- Preclinical
- Lead developer
- Institut Imagine
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
CureEB (also known as CureEB - Institut Imagine) is an antisense oligonucleotide (ASO-tcDNA) therapeutic candidate being developed by Sqy Therapeutics in partnership with the Institut Imagine. It is designed to treat Epidermolysis Bullosa, specifically targeting exon 73 of the COL7A1 gene. The drug acts by inducing exon 73 skipping in COL7A1 transcripts, with the intended goal of restoring functional type VII collagen expression. CureEB is currently in the IND-enabling/preclinical stage of development.
- Other names
- CureEB - Institut Imagine
Beyond the preview
Go deeper on CureEB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CureEB.